Expression of vascular endothelial growth factor and presence of angiovascular cells in tissues from different thyroid disorders

Asako Itoh, Katsumi Iwase, Shin Jimbo, Haruo Yamamoto, Naoki Yamamoto, Masahiro Kokubo, Takao Senda, Akira Nakai, Akio Nagagasaka, Takaaki Nagasaka, Yatsuka Hibi, Teppei Seko

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Vascular endothelial growth factor (VEGF) is involved in tumor angiogenesis and other pathophysiological processes. Materials and methods: We studied the localization of VEGF in human thyroid tissues to clarify its involvement in proliferative processes in a variety of thyroid disorders. Immunohistochemical analysis using purified rabbit polyclonal anti-human VEGF or anti-human CD34 antibody and a streptavidin-biotin peroxidase complex detection system was performed on 58 tissue specimens from 53 patients with different thyroid disorders and 5 normal thyroid glands. Results: Vascular endothelial growth factor was not detected in normal thyroid follicular cells. However, some thyroid tumor cells expressed VEGF in the cytoplasm (papillary carcinoma, 10/18; follicular carcinoma, 1/3; medullary carcinoma, 2/2; follicular adenoma, 3/11; adenomatous goiter, 2/4). In benign follicular adenoma and adenomatous goiter, weak expression of VEGF was found in small areas of the tumor, whereas in malignant thyroid tumors, it was strongly expressed in many cells. However, VEGF was not expressed in anaplastic carcinoma, malignant lymphoma, or Graves' disease. Angiovascular cells stained with CD34 antibody in tissues from different thyroid disorders reflected statistically significant differences in papillary carcinoma, follicular adenoma, and Graves' disease compared with normal thyroids, and such cells showed a trend toward increases in medullary carcinoma and adenomatous goiter. In contrast, low vascularity was observed in anaplastic carcinoma, malignant lymphoma, and follicular carcinoma. Conclusions: Because VEGF probably functions as a hypoxia-inducible angiogenic factor, overexpression of this mediator, concomitant with hypervascularity, may be induced more strongly in malignant thyroid tumors, which need more oxygen to proliferate, than in benign follicular tumors. However, neither VEGF nor CD34 was expressed in anaplastic thyroid carcinoma, which is an extremely poorly differentiated malignant tumor. CD34 but not VEGF was expressed in the hyperplastic thyroid tissues of Graves' disease composed of nontransformed cells. Thus, the expression of VEGF concomitant with CD34 is suggested to reflect both the transformation and differentiation state of malignant tumors.

Original languageEnglish
Pages (from-to)242-248
Number of pages7
JournalWorld Journal of Surgery
Volume34
Issue number2
DOIs
Publication statusPublished - 01-02-2010

Fingerprint

Vascular Endothelial Growth Factor A
Thyroid Gland
Graves Disease
Neoplasms
Goiter
Adenoma
Carcinoma
Medullary Carcinoma
Papillary Carcinoma
Lymphoma
Antibodies
Angiogenesis Inducing Agents
Peroxidase
Cytoplasm
Oxygen
Rabbits

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Itoh, Asako ; Iwase, Katsumi ; Jimbo, Shin ; Yamamoto, Haruo ; Yamamoto, Naoki ; Kokubo, Masahiro ; Senda, Takao ; Nakai, Akira ; Nagagasaka, Akio ; Nagasaka, Takaaki ; Hibi, Yatsuka ; Seko, Teppei. / Expression of vascular endothelial growth factor and presence of angiovascular cells in tissues from different thyroid disorders. In: World Journal of Surgery. 2010 ; Vol. 34, No. 2. pp. 242-248.
@article{4fe3b891ce0e48379e1ae50b0acfbf3f,
title = "Expression of vascular endothelial growth factor and presence of angiovascular cells in tissues from different thyroid disorders",
abstract = "Background: Vascular endothelial growth factor (VEGF) is involved in tumor angiogenesis and other pathophysiological processes. Materials and methods: We studied the localization of VEGF in human thyroid tissues to clarify its involvement in proliferative processes in a variety of thyroid disorders. Immunohistochemical analysis using purified rabbit polyclonal anti-human VEGF or anti-human CD34 antibody and a streptavidin-biotin peroxidase complex detection system was performed on 58 tissue specimens from 53 patients with different thyroid disorders and 5 normal thyroid glands. Results: Vascular endothelial growth factor was not detected in normal thyroid follicular cells. However, some thyroid tumor cells expressed VEGF in the cytoplasm (papillary carcinoma, 10/18; follicular carcinoma, 1/3; medullary carcinoma, 2/2; follicular adenoma, 3/11; adenomatous goiter, 2/4). In benign follicular adenoma and adenomatous goiter, weak expression of VEGF was found in small areas of the tumor, whereas in malignant thyroid tumors, it was strongly expressed in many cells. However, VEGF was not expressed in anaplastic carcinoma, malignant lymphoma, or Graves' disease. Angiovascular cells stained with CD34 antibody in tissues from different thyroid disorders reflected statistically significant differences in papillary carcinoma, follicular adenoma, and Graves' disease compared with normal thyroids, and such cells showed a trend toward increases in medullary carcinoma and adenomatous goiter. In contrast, low vascularity was observed in anaplastic carcinoma, malignant lymphoma, and follicular carcinoma. Conclusions: Because VEGF probably functions as a hypoxia-inducible angiogenic factor, overexpression of this mediator, concomitant with hypervascularity, may be induced more strongly in malignant thyroid tumors, which need more oxygen to proliferate, than in benign follicular tumors. However, neither VEGF nor CD34 was expressed in anaplastic thyroid carcinoma, which is an extremely poorly differentiated malignant tumor. CD34 but not VEGF was expressed in the hyperplastic thyroid tissues of Graves' disease composed of nontransformed cells. Thus, the expression of VEGF concomitant with CD34 is suggested to reflect both the transformation and differentiation state of malignant tumors.",
author = "Asako Itoh and Katsumi Iwase and Shin Jimbo and Haruo Yamamoto and Naoki Yamamoto and Masahiro Kokubo and Takao Senda and Akira Nakai and Akio Nagagasaka and Takaaki Nagasaka and Yatsuka Hibi and Teppei Seko",
year = "2010",
month = "2",
day = "1",
doi = "10.1007/s00268-009-0344-4",
language = "English",
volume = "34",
pages = "242--248",
journal = "World Journal of Surgery",
issn = "0364-2313",
publisher = "Springer New York",
number = "2",

}

Itoh, A, Iwase, K, Jimbo, S, Yamamoto, H, Yamamoto, N, Kokubo, M, Senda, T, Nakai, A, Nagagasaka, A, Nagasaka, T, Hibi, Y & Seko, T 2010, 'Expression of vascular endothelial growth factor and presence of angiovascular cells in tissues from different thyroid disorders', World Journal of Surgery, vol. 34, no. 2, pp. 242-248. https://doi.org/10.1007/s00268-009-0344-4

Expression of vascular endothelial growth factor and presence of angiovascular cells in tissues from different thyroid disorders. / Itoh, Asako; Iwase, Katsumi; Jimbo, Shin; Yamamoto, Haruo; Yamamoto, Naoki; Kokubo, Masahiro; Senda, Takao; Nakai, Akira; Nagagasaka, Akio; Nagasaka, Takaaki; Hibi, Yatsuka; Seko, Teppei.

In: World Journal of Surgery, Vol. 34, No. 2, 01.02.2010, p. 242-248.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Expression of vascular endothelial growth factor and presence of angiovascular cells in tissues from different thyroid disorders

AU - Itoh, Asako

AU - Iwase, Katsumi

AU - Jimbo, Shin

AU - Yamamoto, Haruo

AU - Yamamoto, Naoki

AU - Kokubo, Masahiro

AU - Senda, Takao

AU - Nakai, Akira

AU - Nagagasaka, Akio

AU - Nagasaka, Takaaki

AU - Hibi, Yatsuka

AU - Seko, Teppei

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Background: Vascular endothelial growth factor (VEGF) is involved in tumor angiogenesis and other pathophysiological processes. Materials and methods: We studied the localization of VEGF in human thyroid tissues to clarify its involvement in proliferative processes in a variety of thyroid disorders. Immunohistochemical analysis using purified rabbit polyclonal anti-human VEGF or anti-human CD34 antibody and a streptavidin-biotin peroxidase complex detection system was performed on 58 tissue specimens from 53 patients with different thyroid disorders and 5 normal thyroid glands. Results: Vascular endothelial growth factor was not detected in normal thyroid follicular cells. However, some thyroid tumor cells expressed VEGF in the cytoplasm (papillary carcinoma, 10/18; follicular carcinoma, 1/3; medullary carcinoma, 2/2; follicular adenoma, 3/11; adenomatous goiter, 2/4). In benign follicular adenoma and adenomatous goiter, weak expression of VEGF was found in small areas of the tumor, whereas in malignant thyroid tumors, it was strongly expressed in many cells. However, VEGF was not expressed in anaplastic carcinoma, malignant lymphoma, or Graves' disease. Angiovascular cells stained with CD34 antibody in tissues from different thyroid disorders reflected statistically significant differences in papillary carcinoma, follicular adenoma, and Graves' disease compared with normal thyroids, and such cells showed a trend toward increases in medullary carcinoma and adenomatous goiter. In contrast, low vascularity was observed in anaplastic carcinoma, malignant lymphoma, and follicular carcinoma. Conclusions: Because VEGF probably functions as a hypoxia-inducible angiogenic factor, overexpression of this mediator, concomitant with hypervascularity, may be induced more strongly in malignant thyroid tumors, which need more oxygen to proliferate, than in benign follicular tumors. However, neither VEGF nor CD34 was expressed in anaplastic thyroid carcinoma, which is an extremely poorly differentiated malignant tumor. CD34 but not VEGF was expressed in the hyperplastic thyroid tissues of Graves' disease composed of nontransformed cells. Thus, the expression of VEGF concomitant with CD34 is suggested to reflect both the transformation and differentiation state of malignant tumors.

AB - Background: Vascular endothelial growth factor (VEGF) is involved in tumor angiogenesis and other pathophysiological processes. Materials and methods: We studied the localization of VEGF in human thyroid tissues to clarify its involvement in proliferative processes in a variety of thyroid disorders. Immunohistochemical analysis using purified rabbit polyclonal anti-human VEGF or anti-human CD34 antibody and a streptavidin-biotin peroxidase complex detection system was performed on 58 tissue specimens from 53 patients with different thyroid disorders and 5 normal thyroid glands. Results: Vascular endothelial growth factor was not detected in normal thyroid follicular cells. However, some thyroid tumor cells expressed VEGF in the cytoplasm (papillary carcinoma, 10/18; follicular carcinoma, 1/3; medullary carcinoma, 2/2; follicular adenoma, 3/11; adenomatous goiter, 2/4). In benign follicular adenoma and adenomatous goiter, weak expression of VEGF was found in small areas of the tumor, whereas in malignant thyroid tumors, it was strongly expressed in many cells. However, VEGF was not expressed in anaplastic carcinoma, malignant lymphoma, or Graves' disease. Angiovascular cells stained with CD34 antibody in tissues from different thyroid disorders reflected statistically significant differences in papillary carcinoma, follicular adenoma, and Graves' disease compared with normal thyroids, and such cells showed a trend toward increases in medullary carcinoma and adenomatous goiter. In contrast, low vascularity was observed in anaplastic carcinoma, malignant lymphoma, and follicular carcinoma. Conclusions: Because VEGF probably functions as a hypoxia-inducible angiogenic factor, overexpression of this mediator, concomitant with hypervascularity, may be induced more strongly in malignant thyroid tumors, which need more oxygen to proliferate, than in benign follicular tumors. However, neither VEGF nor CD34 was expressed in anaplastic thyroid carcinoma, which is an extremely poorly differentiated malignant tumor. CD34 but not VEGF was expressed in the hyperplastic thyroid tissues of Graves' disease composed of nontransformed cells. Thus, the expression of VEGF concomitant with CD34 is suggested to reflect both the transformation and differentiation state of malignant tumors.

UR - http://www.scopus.com/inward/record.url?scp=77949273806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949273806&partnerID=8YFLogxK

U2 - 10.1007/s00268-009-0344-4

DO - 10.1007/s00268-009-0344-4

M3 - Article

VL - 34

SP - 242

EP - 248

JO - World Journal of Surgery

JF - World Journal of Surgery

SN - 0364-2313

IS - 2

ER -